Anodyne Nanotech
Dr. Michael Singer is a graduate of Yale University, where he earned his B.S. in Biology, M.D., and Ph.D. in Neuroscience. He is currently Co-Founder and CSO at Cartesian Therapeutics. Prior to that, he was Director of Translational Medicine at Novartis. Dr. Singer was also Co-Founder and CSO at HealthHonors Corporation and Topokine Therapeutics where they were acquired by Healthways and Allergan, respectively. He is a successful serial entrepreneur, healthcare investor, and physician-scientist with a background in transdermal drug delivery.
This person is not in the org chart
Anodyne Nanotech
Anodyne Nanotech is a preclinical-stage biotech company developing differentiated, transdermal forms of high-value drugs. The company’s macroporous microneedle technology provides the first practical and cost-effective platform, Hero Patch, to deliver clinically meaningful doses of macromolecules such as monoclonal antibodies or small molecules (such as ibuprofen) for fast and sustained delivery.